34. 神経線維腫症 Neurofibromatosis Clinical trials / Disease details
臨床試験数 : 133 / 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02104323 (ClinicalTrials.gov) | January 2014 | 26/3/2014 | Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping | Vestibular Schwannoma;Neurofibromatosis Type 2 | Drug: Endostatin | Beijing Tiantan Hospital | Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd | Completed | 16 Years | 30 Years | All | 20 | Phase 2 | China |